Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

The New England Journal of Medicine - In patients with untreated metastatic melanoma, the addition of ipilimumab (anti-CTLA4) to nivolumab (anti-PD1) did not further improve response rate or progression-free survival in PD-L1

Nivolumab Combined with Ipilimumab

Advances in targeted therapy and immunotherapy for melanoma (Review)

A new era of proactive melanoma therapy: hit hard, hit early - Haas - 2018 - British Journal of Dermatology - Wiley Online Library

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, Journal for ImmunoTherapy of Cancer

1694-Melanoma metastatic ipilimumab and nivolumab (induction)

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study - The Lancet Oncology

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations - ScienceDirect

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study - The Lancet Oncology

Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy - Pires da Silva - 2020 - Cancer - Wiley Online Library

Figure 3 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Nivolumab and Relatlimab for Advanced Melanoma - NCI

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain